LABORATORY PARAMETERS AND THEIR RELATIONS WITH DISEASE OUTCOME IN PATIENTS WITH NON-HODGKIN FOLLICULAR LYMPHOMA – SINGLE CENTRE FIVE-YEAR FOLLOW-UP
Abstract
Introduction/Objective: Follicular lymphoma, a subtype of non-Hodgkin lymphoma, is the second most common non-Hodgkin lymphoma and the most frequent indolent lymphoma. Although rare, this disease may exhibit aggressive behavior, a tendency toward complications, as well as resistance to administered therapy and frequent relapses.
This study aimed to analyze laboratory parameters at the time of diagnosis and their association with disease outcome, complications, treatment response, and survival.
Material and methods: A total of 47 patients diagnosed with follicular lymphoma between 2018 and January 2024 were analyzed at our center. Baseline laboratory parameters included complete blood count, hemostasis parameters (PT, aPTT, fibrinogen, D-dimer), and biochemical parameters. During the course of the disease, treatment response to first-line therapy, progression-free survival, and overall survival were evaluated.
Results: Complete blood count parameters, as well as most biochemical parameters, showed no correlation with disease course. Complete remission was achieved in patients with lower LDH levels (p = 0.029), while overall survival was longer in patients with lower fibrinogen levels (p = 0.019), a higher percentage of monocytes (p = 0.007), and lower D-dimer levels (p = 0.000). Progression-free survival was associated with lower fibrinogen levels (p = 0.019), lower D-dimer levels (p = 0.031), lower LDH levels (p = 0.019), and a higher percentage of peripheral blood monocytes (p = 0.005). Patients with initially elevated D-dimer levels had a PFS of 24.50 ± 4.81 months, whereas those with D-dimer levels within the reference range had a PFS of 36.48 ± 5.99 months (p = 0.015).
Conclusion: In our center's experience, hemostasis parameters, particularly fibrinogen and D-dimer, showed a significant correlation with disease course.
References
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720-48. doi: 10.1038/s41375-022-01620-2. Erratum in: Leukemia. 2023 Sep;37(9):1944-51. doi: 10.1038/s41375-023-01962-5.
Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15;140(11):1229-53. doi: 10.1182/blood.2022015851. Erratum in: Blood. 2023 Jan 26;141(4):437. doi: 10.1182/blood.2022019016.
Cerhan JR. Epidemiology of Follicular Lymphoma. Hematol Oncol Clin North Am. 2020 Aug;34(4):631-46. doi: 10.1016/j.hoc.2020.02.001.
Hübel K, Ghielmini M, Ladetto M, Gopal AK. Controversies in the Treatment of Follicular Lymphoma. Hemasphere. 2020 Jan 10;4(1):e317. doi: 10.1097/HS9.0000000000000317.
Cartron G, Trotman J. Time for an individualized approach to first-line management of follicular lymphoma. Haematologica. 2022 Jan 1;107(1):7-18. doi: 10.3324/haematol.2021.278766.
Rahchamani M, Sedghi M, Hakimi A, Nejatianfar M, Javaheri T, Tavakoli R, et al. Prognostic value of red blood cell distribution width and D-Dimer in diffuse large B-cell lymphoma: Systematic review and meta-analysis. Cancer Rep (Hoboken). 2024 Jan;7(1):e1936. doi: 10.1002/cnr2.1936.
Huang H, Fan L, Fu D, Lin Q, Shen J. High pretreatment plasma D-dimer levels predict poor survival in patients with diffuse large B-cell lymphoma in the real world. Transl Cancer Res. 2021 Apr;10(4):1723-31. doi: 10.21037/tcr-20-2908.
Liu B, Li B, Zhou P, Yue W, Wang T, Wang J, et al. Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL). Clin Chim Acta. 2018 Jul;482:191-8. doi: 10.1016/j.cca.2018.04.013.
Geng YD, Chen YR, Jin J, Wang XD, Zhang S, Li DJ. Prognostic Value of D-Dimer in Patients with Diffuse Large B-cell Lymphoma: A Retrospective Study. Curr Med Sci. 2019 Apr;39(2):222-7. doi: 10.1007/s11596-019-2023-5.
Bi XW, Wang L, Zhang WW, Sun P, Yan SM, Liu PP, et al. High Pretreatment D-Dimer Levels Correlate with Adverse Clinical Features and Predict Poor Survival in Patients with Natural Killer/T-Cell Lymphoma. PLoS One. 2016 Mar 31;11(3):e0152842. doi: 10.1371/journal.pone.0152842.
Mazur G, Poreba M, Wrobel T, Poreba R, Pyszel A, Beck B, et al. Correlation between Angiogenic and Coagulation-Fibrinolysis Factors and Stage of Disease in Non Hodgkin’s Lymphoma Patients. Blood. 2005 Nov 16;106(11):4678. doi: 10.1182/blood.V106.11.4678.4678.
Tarek N, Younes S, Suliman MA, Ibrahim GA. Predictive utility of plasma fibrinogen level in B-cell lymphoma: a single-center cohort study. Egypt. J. Haematol. 2023 Apr-Jun;48(2):155-60. doi: 10.4103/ejh.ejh_67_22.
Živković E, Mitrović-Ajtić O, Subotički T, Ivanović J, Otašević V, Đikić D, et al. Thromboinflammatory Biomarkers in Lymphomas: Linking Inflammation to Thrombosis Risk. Int J Mol Sci. 2025 Feb 26;26(5):2058. doi: 10.3390/ijms26052058.
